Oncolytic viruses: Finally delivering

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 357-361

  Seymour, Leonard W ^a   Fisher, Kerry D ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

pro inflammatory; self amplifying therapeutic agent; systemic delivery; targeted oncolytic vaccines; tumour specific viruses; virotherapy

Indexed keywords

CANCER VACCINE; INTERFERON; ONCOLYTIC VIRUS;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL KILLING; COST EFFECTIVENESS ANALYSIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; HUMAN; IMMUNOGENICITY; INFLAMMATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; VIRUS PARTICLE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84954348889     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.481     Document Type: Review

References (34)

1. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA. (2008). Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene. 27(22): 3081-3090.
2. Bauzon M, Hermiston T. (2014). Armed therapeutic viruses - A disruptive therapy on the horizon of cancer immunotherapy. Front Immunol. 5: 74.
3. Bauzon M, Hermiston TW. (2012). Oncolytic viruses: the power of directed evolution. Adv Virol 2012: 586389.
4. Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH. (2015). Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Curr Opin Virol. 13: 49-54.
5. Calvo E, Gil-Martin M, Machiels J-P, Rottey S, Cubillo A, Salazar R, Mardjuadi F, Geboes K, Ellis C, Beadle J, Blanc C. (2014). A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors. J Clin Oncol. 32(5s): abstract 3103.
6. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, Subr V, Ulbrich K, Gilbert RJ, Fisher KD, Finberg RW, Seymour LW. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-Adenovirus receptor and complement receptor 1. Blood. 113(9): 1909-1918.
7. Chiocca EA, Rabkin SD. (2014). Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2(4): 295-300.
8. Clive KS, Tyler JA, Clifton GT, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. (2010). Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. Expert Rev Vaccines. 9(5): 519-525.
9. Di Y, Seymour L, Fisher K. (2014). Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 21(4): 440-443.
10. Farassati F, Yang AD, Lee PW. (2001). Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 3(8): 745-750.
11. Fisher K. (2006). Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther. 8(4): 301-313.
12. Gil Martin M, Cubillo A, Machiels J, Rottey S, Mardjuadi F, Geboes K, Salazar R, Beadle J, Ellis C, Fisher K, Blanc C, Calvo E. (2014). A phase 1 study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously - Analysis of dose expansion and repeat cycle cohorots in patients with metastatic colorectal cancer (mCRC). Ann Oncol. 25(suppl 4): lv361-lv372.
13. Guo ZS, Liu Z, Bartlett DL. (2014). Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 4: 74.
14. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell. 144(5): 646-674.
15. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 19(3): 329-336.
16. Ilett E, Kottke T, Donnelly O, Thompson J, Willmon C, Diaz R, Zaidi S, Coffey M, Selby P, Harrington K, Pandha H, Melcher A, Vile R. (2014). Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther. 22(10): 1851-1863.
17. Kelly E, Russell SJ. (2007). History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 15(4): 651-659.
18. Kirn D. (2001). Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther. 1(3): 525-538.
19. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. (2007). Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med. 4(12): e353.
20. Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 3(6): e2409.
21. Li S, Zhu M, Pan R, Fang T, Cao YY, Chen S, Zhao X, Lei CQ, Guo L, Li CM, Jokitalo E, Yin Y, Shu HB, Guo D. (2015). Pivotal role for PTEN in the induction of type I interferon and antiviral response in vivo. Nature Immunol; e-pub ahead of print 21 December 2015; doi: 10.1038/ni.3311.
22. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. (2014). Going viral with cancer immunotherapy. Nat Rev Cancer. 14(8): 559-567.
23. Liu TC, Hwang T, Park BH, Bell J, Kirn DH. (2008). The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 16(9): 1637-1642.
24. Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, Phipps S, Hale S, Mautner V, Seymour LW, Fisher KD. (2006). Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 14(1): 118-128.
25. O'Shea CC, Soria C, Bagus B, McCormick F. (2005). Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell. 8(1): 61-74.
26. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK, Gerdemann U, Leen AM, Kairemo K, Oksanen M, Haavisto E, Holm SL, Karioja-Kallio A, Kauppinen S, Partanen KP, Laasonen L, Joensuu T, Alanko T, Cerullo V, Hemminki A. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 72(7): 1621-1631.
27. Puzanov I, Milhern M, Andtbacka R, Minor D, Hamid O, Li A, Chastain M, Gorski K, Anderson A, Vanderwalde A, Chou J, Kaufman H. (2014). Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. J Clin Oncol. 32(5s): abstract 9029.
28. Russell SJ, Peng KW, Bell JC. (2012). Oncolytic virotherapy. Nat Biotechnol. 30(7): 658-670.
29. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, secondgeneration oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 27(34): 5763-5771.
30. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostatespecific antigen-Targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 14(1): 107-117.
31. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med. 6(7): 821-825.
32. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, Kostense S, Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst O, Koel B, van Meerendonk M, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M. (2003). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 77(15): 8263-8271.
33. Whilding LM, Archibald KM, Kulbe H, Balkwill FR, Oberg D, McNeish IA. (2013). Vaccinia virus induces programmed necrosis in ovarian cancer cells. Mol Ther. 21(11): 2074-2086.
34. Zeh HJ, Downs-Canner S, McCart JA, Guo ZS, Rao UN, Ramalingam L, Thorne SH, Jones HL, Kalinski P, Wieckowski E, O'Malley ME, Daneshmand M, Hu K, Bell JC, Hwang TH, Moon A, Breitbach CJ, Kirn DH, Bartlett DL. (2015). First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther. 23(1): 202-214.